Cabozantinib shows significant first-line activity for differentiated thyroid cancer

February 13, 2018, American Society for Radiation Oncology

Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive iodine (RAI). Thirty-four of 35 patients in the trial experienced a reduction in tumor size following treatment with the targeted kinase inhibitor, and more than half experienced reductions in excess of 30 percent. The study will be presented today in an online news briefing and at the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona.

"The recent introduction of targeted therapy with kinase inhibitors for with advanced thyroid created a possible path to control the cancers of patients we previously could treat only with supportive care. Our trial shows that cabozantinib also is an active agent and could significantly improve the care of patients with advanced disease," said Marcia S. Brose, MD, PhD, an associate professor in the Department of Otorhinolaryngology: Head and Neck surgery and the director of the Center for Rare Cancers and Personalized Therapy at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.

Five years ago, there were no federally approved curative options for RAI-refractory differentiated . Two have come to market for advanced DTC in the years since, but responses to these agents are not durable and when patients progress they need additional therapeutic options.

"While prior agents that attack the vascular endothelial growth factor (VEGF) receptor have been active in advanced DTC, patients on these therapies eventually progress or are unable to tolerate the drug," explained Dr. Brose. "Our positive trial results indicate that cabozantinib offers an additional option to shrink patients' tumors and provide an additional progression-free period."

NCT02041260 is a single-arm, open-label phase II study of cabozantinib in the first-line setting for metastatic, RAI-refractory, unresectable or locally-advanced thyroid carcinoma. Thirty-five patients were enrolled between March 2014 and August 2017. Patients in the trial were administered 60 mg of oral cabozantinib each day. Median time on the study was 35 weeks (range 3-197), and 16 patients remain enrolled as of February 6, 2018.

Most patients had papillary histology (63%), followed by poorly differentiated (29%) and Hürthle cell (9%) carcinomas. Patients had not received prior kinase inhibitor therapy. Median patient age was 65 years (range 45-84), and 49 percent of the enrolled patients were male.

Thirty-four of the 35 patients experienced tumor shrinkage. Partial response (i.e., greater than 30%) was achieved in 19 of the 35 patients (with short follow-up for four patients enrolled at the end of the study), for an overall response rate of 54 percent. Duration of partial responses ranged from 11 weeks to more than 174 weeks. Stable disease was achieved in 15 patients, with duration of stability ranging from eight weeks to more than 142 weeks. Cancer progressed in six patients, with a median time to progression of 35 weeks (range 8-40).

Cabozantinib was well-tolerated, although dose interruptions and dose adjustments were needed for the majority of patients (23 of 35) at some point on treatment. Treatment-related adverse events of any grade were experienced by all patients (100%). The most common adverse events attributable to cabozantinib included hyperglycemia (28 patients, 80%), diarrhea (27, 77%), malaise/fatigue (26, 74%) and weight loss (25, 71%). The majority of these adverse events were grades 1 and 2. Grade 3 or higher that occurred in more than one patient included hypertension (5 patients, 14%), increased lipase (3, 9%), weight loss (2, 6%), pulmonary embolism (2, 6%) and hyponatremia (2, 6%).

Explore further: Results from Alliance CABOSUN trial lead to US FDA approval of extended indication

More information: The abstract, "A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting," will be presented in detail during the Oral Abstract Session at the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Arizona.

Related Stories

Results from Alliance CABOSUN trial lead to US FDA approval of extended indication

December 20, 2017
The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX (cabozantinib) tablets for the ...

Nivolumab immunotherapy safe, feasible during chemoradiation for adv. head and neck cancer

February 13, 2018
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced ...

Phase II trial shows activity of durvalumab in recurrent/metastatic head and neck cancer

February 13, 2018
Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow ...

New immunotherapy combination tolerable, effective in patients with advanced kidney cancer

February 11, 2018
Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients ...

Cabozantinib improves progression-free survival in metastatic renal cell carcinoma

October 10, 2016
Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented today at the ESMO 2016 Congress in Copenhagen.

Lower-dose radiation effective, safe for HPV+ head and neck cancer after induction chemo

February 13, 2018
Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the human papillomavirus (HPV), including those with advanced nodal disease, can receive substantially lower ...

Recommended for you

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Scientists discover chemical which can kill glioblastoma cells

August 15, 2018
Aggressive brain tumour cells taken from patients self-destructed after being exposed to a chemical in laboratory tests, researchers have shown.

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.